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Integration-deficient lentiviral vectors (IDLVs) have been 
shown to transduce a wide spectrum of target cells and 
organs in vitro and in vivo and to maintain long-term 
transgene expression in nondividing cells. However, epi-
genetic silencing of episomal vector genomes reduces 
IDLV transgene expression levels and renders these safe 
vectors less efficient. In this article, we describe for the 
first time a complete correction of factor IX (FIX) defi-
ciency in hemophilia B mice by IDLVs carrying a novel, 
highly potent human FIX cDNA. A 50-fold increase in 
human FIX cDNA potency was achieved by combining 
two mechanistically independent yet synergistic strat-
egies: (i) optimization of the human FIX cDNA codon 
usage to increase human FIX protein production per 
vector genome and (ii) generation of a highly cata-
lytic mutant human FIX protein in which the arginine 
residue at position 338 was substituted with leucine. 
The enhanced human FIX activity was not associated 
with liver damage or with the formation of human 
FIX-directed inhibitory antibodies and rendered IDLV-
treated FIX-knockout mice resistant to a challenging 
tail-clipping assay. A novel S1 nuclease-based B1-quan-
titative polymerase chain reaction assay showed low 
levels of IDLV integration in mouse liver. Overall, this 
study demonstrates that IDLVs carrying an improved 
human FIX cDNA safely and efficiently cure hemophilia 
B in a mouse model.
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publication 7 January 2014. doi:10.1038/mt.2013.188
IntroductIon
In a recent human clinical trial for the treatment of β-thalassemia, 
lentiviral vectors integrated into the third intron of the proto-
oncogene HMGA2 led to overexpression of truncated HMGA2 
mRNA and to benign clonal expansion.1 Molecular analysis 
of the mechanisms involved in the dysregulation of prolifera-
tion following retro- and lentiviral vector integration implicated 
vector-contained regulatory elements in transcriptional and 
posttranscriptional alterations of host oncogene expression.1–3 
These included enhancer elements, polyadenylation signals, and 
splice sites (either major or cryptic). The range of mechanisms by 
which integrating vectors can alter host gene expression renders 
the task of developing mutation-free lentiviral vectors more chal-
lenging and has been the impetus for the development of various 
integration-deficient lentiviral vector (IDLV) systems.
To date, most IDLVs have been generated by packaging 
genomic vector RNAs into vector particles containing class I 
integrase mutants, which render the vector integration defective 
and yet support all other vector functions required for efficient 
gene transfer.4,5 IDLVs maintain long-term expression in slowly 
dividing or nondividing cells in vitro and in vivo.6–15 However, 
recent studies have demonstrated that epigenetic silencing ren-
ders IDLV transgene expression inefficient.6,16,17 Given the tran-
scriptional silencing of episomal human immunodeficiency virus 
(HIV)-1-based vectors, achieving effective gene replacement 
therapy on systemic administration of IDLVs remains a major 
challenge. Indeed, in a recent preclinical study by Mátrai et al., 
intravenous administration of IDLVs carrying a canine factor IX 
cDNA resulted in a merely transient detectable increase (1–2%) 
in canine factor IX (cFIX) activity in hemophilia B mice.18 The 
relatively high dose of IDLVs (total p24gag 260 µg) used by Mátrai 
et al. suggests that a further increase in IDLV dosage would not 
achieve long-term therapeutic levels of FIX activity in hemo-
philia B mice.
In this article, we report on the development of novel lentiviral 
vectors carrying a highly potent human FIX cDNA as a means 
for curing hemophilia B mice through systemic administration 
of IDLVs. Two strategies for improving human FIX cDNA func-
tion were combined to synergistically enhance overall human 
FIX potency. Specifically, a fivefold increase in human FIX pro-
tein production per lentiviral vector genome was obtained by 
optimizing the codon usage of the human FIX cDNA. We fur-
ther improved the effectiveness of vector-delivered human FIX by 
using more catalytically active human FIX mutants. This strategy 
was premised on earlier studies showing that the FIX variants 
R338A (the arginine 338 residue replaced by alanine) and R338L 
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were three- to sevenfold more catalytically active than the wild-
type (WT) human FIX protein.19,20 In line with these studies, an 
eightfold increase in human FIX-specific activity was demon-
strated in vitro by lentiviral vectors carrying the R338L human 
FIX. To maximize the effectiveness of vector-delivered human 
FIX, the two aforementioned strategies of improving human FIX 
cDNA were combined to generate novel codon-optimized human 
FIX cDNAs encoding a highly catalytically active R338L human 
FIX mutant. Indeed, the increased human FIX production and 
the enhanced catalytic activity of the R338L mutant synergistically 
increased overall human FIX activity per vector genome by >50-
fold.21,22 Of note, systemic administration of IDLVs carrying the 
novel human FIX cDNA achieved complete long-term cure (with 
maximal human FIX activity >500%) of hemophilia B in mice. 
Vector-treated mice survived a challenging tail-clipping assay. 
Furthermore, vector administration did not induce liver dam-
age or the development of human FIX-directed humoral immune 
response.
results
lentiviral vectors carrying highly potent human FIX 
cdnAs exhibit superior therapeutic potential
To facilitate effective IDLV-mediated gene replacement therapy 
for hemophilia B, we sought to enhance the therapeutic potency 
of IDLV-delivered human FIX cDNAs. With that aim, a series 
of WT and codon-optimized (Opt.) human FIX cDNA variants, 
with the arginine 338 residue replaced by alanine (R338A), glu-
tamine (R338Q), or leucine (R338L), were cloned into a bicis-
tronic lentiviral vector expressing the green fluorescent protein 
and blasticidin fusion protein (Figure 1a). Premised on ear-
lier studies,19,20 we expected that the novel human FIX cDNAs 
would be more potent than their WT counterpart. To test this 
hypothesis, HepG2 cells were transduced with the aforemen-
tioned lentiviral vectors and selected for blasticidin resistance. 
The efficiency of human FIX production was evaluated by nor-
malizing the concentration of secreted human FIX to the vector 
copy number (VCN). Specific clotting activities of the variants 
and WT human FIX proteins secreted into the culture medium 
were determined by a standard activated partial thromboplastin 
time assay, normalized to human FIX protein concentration. The 
overall effect of the various human FIX cDNA modifications on 
human FIX clotting activity was calculated as the multiplication 
product of the fold increase in human FIX production per vector 
genome and the fold increase in human FIX-specific activity. As 
shown in Figure 1b, lentiviral vectors carrying codon-optimized 
human FIX cDNAs expressed nearly fivefold more human FIX 
protein per vector genome than vectors carrying the WT human 
FIX cDNA. All three human FIX variant proteins carrying the 
338-residue mutations exhibited increased clotting activity. Of 
the three codon-optimized mutations, the R338L variant exhib-
ited the highest specific activity (1964.4 IU/mg), which is 11-fold 
higher than the parental WT human FIX clotting activity (Figure 
1b). Furthermore, the overall clotting activity per vector genome 
obtained from the HepG2 cell line (expressing the codon-opti-
mized R338L human FIX variant) was >50-fold higher than the 
clotting activity yielded by WT human FIX-expressing cells. 
Encouraged by this result, we sought to evaluate the therapeutic 
potential of IDLVs carrying the codon-optimized R338L human 
FIX in vivo.
IdlVs carrying codon-optimized r338l human FIX 
cdnA mediate complete long-term correction of FIX 
deficiency in vivo
To evaluate IDLVs’ ability to correct FIX deficiency in a mouse 
model of hemophilia B, the codon-optimized R338L human FIX 
cDNA was incorporated into a lentiviral vector under the control 
of the liver-specific human α1-antitrypsin promoter (pTK1340; 
Figure 2a). Vector particles containing either the WT HIV-1 
integrase (integrase-competent lentiviral vector (ICLV)) or 
the D64E integrase mutant (IDLV) were generated by transient 
transfection.23 Escalating doses of IDLVs (45, 65, 200, and 250 µg 
p24gag) and ICLVs (7, 20, and 65 µg p24gag) were administered to 
C57BL/6 hemophilia B mice by a single intraperitoneal injection. 
Concentration of human FIX protein and its clotting activity in 
Figure 1 codon optimization and r338 mutations synergistically 
enhance the efficacy of human FIX cdnA delivered by lentiviral vec-
tor in vitro. (a) Depiction of the lentiviral vector backbone used in this 
study. All vectors contain 5′ and large U3-deleted 3′ long terminal repeats 
(5′LTR and ∆U3 3′LTR), packaging signal (Ψ), central polypurine tract 
(cPPT), cytomegalovirus promoter, human FIX transgene, internal ribo-
some entry site (IRES), a fusion protein encoded by the green fluorescent 
protein (GFP) reporter and the blasticidin resistance genes, woodchuck 
hepatitis virus posttranscriptional regulatory element (WPRE), and poly-
purine tract (PPT). (b) Concentration and clotting activity of wild-type 
(WT) and modified human FIX proteins expressed in HepG2 cells trans-
duced with integrase-competent lentiviral vectors harboring a series 
of human FIX cDNAs, including WT and three R338 mutants (R338A, 
R338Q, and R338L) either in the background of the parental human FIX 
cDNA or following codon optimization. Concentration of human FIX in 
culture medium (obtained from HepG2 cell lines transduced with the 
aforementioned human FIX cDNAs) was determined by enzyme-linked 
immunosorbent assay and normalized to vector copy number (VCN) as 
determined by quantitative polymerase chain reaction. The human FIX-
specific activity was determined by an activated partial thromboplastin 
time assay normalized to human FIX level. Each sample was analyzed 
in duplicates. Data were normalized to cell number and VCN and are 
presented as means ± SEM from triplicate samples. The overall effect 
of the various human FIX cDNA modifications on human FIX clotting 
activity was calculated as the multiplication product of the fold increase 
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mice plasma were periodically determined by the human FIX 
enzyme-linked immunosorbent assay and activated partial 
thromboplastin time assay, respectively. As shown in Figure 2b–g, 
all IDLV-treated mice exhibited long-term therapeutic concentra-
tion and activity levels of human FIX in a dose-dependent man-
ner. Note that at 1 year after vector administration, the average 
plasma human FIX concentration and activity in mice treated 
with the lowest dose of IDLV (45 µg p24gag) were 34.8 ng/ml and 
15.5%, respectively (Figure 2b), which is sufficient to significantly 
improve the clinical status of patients with hemophilia B.24 As 
expected, ICLVs were found to be more efficacious than IDLVs 
at obtaining therapeutic human FIX levels in hemophilia B mice. 
At 1 year postinjection, human FIX activity in mice treated with 
65 µg p24gag of ICLV or IDLV was 194% and 29.7%, respectively. 
Figure 2 long-term expression of therapeutic levels of r338l human FIX in hemophilia B mice. (a) Depiction of the lentiviral vector (pTK1340) 
from which the codon-optimized R338L human FIX is expressed under the control of the human α1-antitrypsin promoter (hAAT). (b–g) Levels of 
human FIX concentration (ng/ml) and clotting activity (percentage normal human FIX clotting activity as measured in vitro) in hemophilia B mice 
treated with escalating doses of integration-deficient lentiviral vectors (IDLVs): (b) 45 µg p24gag, (c) 65 µg p24gag, and (d) 200 and 250 µg p24gag , 
compared with mice treated with (e) integrase-competent lentiviral vectors (ICLVs): (e) 7 and 20 µg p24gag, (f) 54 µg p24gag, and (g) 65 µg p24gag. All 
samples were measured in duplicates. Data are presented as mean ± SEM. cPPT, central polypurine tract; LTR, long terminal repeat; PBS, phosphate-
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However, at 20 weeks postinjection, the average human FIX con-
centration and activity in mice administered with the highest dose 
of IDLV (250 µg p24gag) was 3,250 ng/ml and 675%, respectively. 
We further directly evaluated the ability of IDLVs carrying 
the codon-optimized R338L human FIX cDNA to correct FIX 
deficiency in vivo. Hemophilia B mice treated with total doses of 
either 200 or 250 µg p24gag IDLVs were subjected to a challeng-
ing tail-clipping assay. As shown for the first time (Figure 3a and 
Table 1), all seven IDLV-treated mice survived the bleeding chal-
lenge and demonstrated significantly reduced blood loss. All seven 
untreated hemophilia B mice exhibited massive blood loss, which 
necessitated euthanasia (Table 1). Furthermore, in contrast with 
earlier reports,18,25,26 these data suggest that therapeutically effec-
tive doses of IDLVs and ICLVs do not elicit significant humoral 
or cellular immune responses against vector-delivered human FIX 
or vector-transduced cells, respectively. Of note, necropsy of two 
mice revealed tumor development. However, the low VCN in the 
tumors’ DNA suggested that tumor development was not associ-
ated with insertional mutagenesis (Supplementary Figure S1 and 
Supplementary Table S1).
lack of immune response to human FIX and vector-
transduced cells
To identify potential vector-induced immunotoxicity, we sought 
to determine whether either humoral or cellular immune response 
to human FIX antigen or to vector-transduced hepatocytes, 
respectively, had evolved following vector administration and 
human FIX expression. Thus, mouse plasma samples obtained 
before and at various time points after vector administration 
were tested for the presence of inhibitory antibodies to human 
FIX. In addition, plasma levels of liver enzymes were determined 
as a means to detect liver damage mediated by cellular cytotox-
icity to vector-transduced hepatocytes. As shown in Figure 3b, 
human FIX activity was not affected by undiluted mouse plasma, 
thus ruling out the possibility that inhibitory antibodies to human 
FIX had developed following vector administration. In addition, 
normal levels of liver enzymes found in all tested mouse plasma 
samples indicated that liver transduction with lentiviral vectors, 
carrying human FIX expression under the control of the human 
α1-antitrypsin promoter, did not induce hepatocyte-directed 
immune response (Figure 3c). Of note, in contrast with earlier 
studies,18,25,26 the aforementioned data demonstrated that main-
taining therapeutic levels of human FIX expression from conven-
tional lentiviral vectors does not necessitate miRNA-mediated 
knockdown of human FIX expression in antigen-presenting cells.
Figure 3 Integration-deficient lentiviral vector (IdlV) delivery of 
the codon-optimized r338l human FIX rendered hemophilia B 
mice resistant to tail-clipping injury without inducing immunologic 
adverse effects. (a) Functional clotting assay in vivo. Hemophilia B 
mice were intraperitoneally injected with IDLVs carrying the codon-
optimized R338L human FIX cDNA under the control of the human 
α1-antitrypsin promoter (pTK1340), with doses of either 200 µg (n = 
4) or 250 µg (n  = 3) p24gag. At 20 weeks postvector administration, 
treated mice were challenged with a tail-clipping assay. Total volume 
of blood lost in 15 min was measured in seven vector-treated mice 
and compared with blood loss of tail-clipped wild-type (n = 6) and 
phosphate-buffered saline (PBS)-injected hemophilia B mice (n = 11). 
P value was assessed by a paired Student’s t-test. (b) Lack of neutral-
izing antibodies directed to human FIX protein in IDLV-treated mice. A 
modified Bethesda assay was used to detect the emergence of inhibi-
tory human FIX antibodies. Plasma samples were collected from the 
aforementioned IDLV-treated hemophilia B mice (250 µg p24gag, n = 3) 
before (prebleed) and at various time points postvector administration 
and were analyzed for the presence of inhibitory antibodies. Plasma 
samples obtained from a naive (untreated) mouse and from the human 
FIX inhibitor-producing mouse (a hemophilia B mouse injected with 
purified human FIX protein and exhibiting 28 Bethesda units (BU)/ml), 
were used as negative and positive control, respectively. (c) Evaluation 
of vector-mediated hepatotoxicity. To detect liver damage induced by 
either uptake of vector particles or due to human FIX production, levels 
of alanine aminotransferase (ALT) were determined in mouse plasma 
obtained before and periodically after vector administration. Samples 
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Biodistribution and integration of IclVs and IdlVs in 
hemophilia B mice
To characterize the ICLV and IDLV biodistribution following a 
single intraperitoneal administration of codon-optimized R338L 
human FIX, multiplex quantitative polymerase chain reaction 
(qPCR) analysis was used on genomic DNA samples from differ-
ent mouse tissues obtained at 1 year postvector administration 
(duration of experiments). As shown in Figure 4a, the highest 
VCN per host genome of both ICLVs (65 µg p24gag) and IDLVs 
(250 µg p24gag) was found in liver tissues, with 1.0 and 8.2 VCN, 
respectively. In spleen tissues, the VCN of ICLVs and IDLVs was 
0.4 and 0.9, respectively. As expected, neither IDLV nor ICLV 
vector genomes were detected in brain tissues. Interestingly, up 
to 0.06 VCN of ICLVs was found in bone marrow samples. This 
relatively efficient in vivo bone marrow transduction is in line with 
the data presented in an earlier study by Pan et al.27 Due to the loss 
of episomal vector genomes, a VCN of merely 0.04 was found in 
actively dividing bone marrow cells at 1 year post high-dose (250 
µg p24gag) IDLV administration. However, these findings raised 
the possibility that some of the IDLV genomes might have ille-
gitimately integrated into the host chromatin by integrase-inde-
pendent mechanisms. Recent studies16,28 characterizing the rates 
of residual IDLV integration in vitro demonstrated that up to 1 in 
200 IDLV genomes are likely to integrate into a host cell genome. 
To accurately compare the number of integrated viral genomes in 
liver tissues at 1 year postintraperitoneal administration of either 
ICLVs or IDLVs, we established and used a modified B1-qPCR 
assay (Supplementary Data), which was described earlier by 
Tervo et al.29 As shown in Figure 4b, the levels of integrated vec-
tor genomes following administration of ICLV (65 µg p24gag) in 
liver tissues were found to be more than fourfold higher than the 
IDLV levels (250 µg p24gag). Note that the average total IDLV vec-
tor genomes in liver tissues were eightfold higher than the total 
ICLV genomes, indicating that the level of IDLV integration is 
nearly 35-fold lower than the level of ICLV integration. To further 
characterize the mechanism of IDLV integration, unique exactly 
mapped integration sites (ISs) of IDLVs (257 ISs) and ICLVs 
(1,697 ISs) were isolated by non-restrictive linear amplification-
mediated (LAM)-PCR and LAM-PCR and were sequenced by 454 
pyrosequencing.30,31 In line with an earlier study,18 18.6% of IDLV 
ISs showed long terminal repeat deletions >2 nucleotides, whereas 
only 3.1% of ISs retrieved from ICLV-administered samples 
showed such deletions. These findings support the notion that 
IDLVs carrying the codon-optimized R338L human FIX cDNA 
can impart a long-term cure of hemophilia B with minimal geno-
toxic risks. However, to directly evaluate the added biosafety value 
of IDLVs, we calculated the therapeutic/genotoxic index (TGI) of 
the lentiviral vectors used in this study as the overall increase in 
human FIX percentage activity per integrated vector genome in 
vivo. As shown in Figure 4c, at 1 year postsystemic administration 
of lentiviral vectors (250 µg p24gag), the calculated TGI of IDLVs 
was significantly (nearly 12-fold) higher than the TGI of its inte-
grated counterparts. The findings of this study provide the first in 
vivo experimental evidence that systemic administration of IDLVs 
is a safe and effective gene replacement methodology exhibiting 
table 1 tail-clipping assay as a means to functionally evaluate 
 clotting activity in vivo in IdlV-treated hemophilia B mice
Animal cohort recurrent bleeding survival
Wild-type No 6/6
Hemophilia B (untreated) Yes 0/7
Hemophilia B IDLV/codon-optimized 
R338L human FIX (i.p. 200–250 µg p24gag)
No 7/7
Abbreviations: IDLV, integration-deficient lentiviral vector; i.p., intraperitoneal.
IDLV-treated hemophilia B mice survived a challenging tail-clipping assay. Two 
cohorts of hemophilia B mice were intraperitoneally injected with IDLVs carrying 
the codon-optimized R338L human FIX (pTK1340) at doses of 200 µg (n = 
4) and 250 µg (n = 3) p24gag. At 20 weeks postinjection, vector-treated mice, 
phosphate-buffered saline-injected hemophilia B mice (n = 7), and wild-type 
C57BL/6 mice (n = 6) were subjected to a tail-clipping assay. The ability of the 
mice to survive the procedure and to efficiently prevent recurrent bleeding was 
determined.
Figure 4 Analysis of total and integrated vector copy number (Vcn) 
of integration-deficient lentiviral vectors (IdlVs) and integrase-
competent lentiviral vectors (IclVs) in mouse tissues demonstrated 
low illegitimate integration and a high therapeutic/genotoxic index 
of IdlVs. VCN in tissues was assessed at 1 year postintraperitoneal vec-
tor administration of ICLVs (65 µg p24gag) and IDLVs (250 µg p24gag). 
(a) A multiplex quantitative polymerase chain reaction analysis of total 
VCN per host genome of ICLV and IDLV in mouse tissues. (b) The rela-
tive integration level of IDLVs (n = 3) normalized to the level of ICLV 
integration in mouse livers was analyzed by the S1/B1-quantitative poly-
merase chain reaction assay. Integrated VCN (iVCN) in a single mouse 
liver treated with ICLVs (65 µg p24gag) served as a baseline (valued as 
1.00) for the analysis of two additional ICLV-treated mice and to estab-
lish the standard curve in the analysis of three IDLV (250 µg p24gag)-
treated mice. The relative therapeutic/genotoxic index (TGI) of ICLV and 
IDLV vectors was calculated as the overall increase in human FIX percent-
age activity per iVCN. (c) Graph demonstrating TGI values of IDLVs and 
ICLVs following intraperitoneal administration to hemophilia B mice. P 
value was assessed by a paired Student’s t-test. BM, bone marrow.
IDLV 250 µg (n = 3)
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reduced genotoxicity. Moreover, therapeutic efficacy was not asso-
ciated with an immune response to either the IDLV-delivered 
transgene or the vector-transduced hepatocytes.
dIscussIon
The IDLV system offers an efficient approach to ferry large genetic 
cargoes to dividing and nondividing cells in vitro and in vivo, 
without posing the risk of insertional mutagenesis that is associ-
ated with ICLVs. However, epigenetic silencing of IDLVs renders 
this promising gene delivery system inefficient for in vivo applica-
tions that require systemic vector administration.6,18 In this study, 
we sought to use the codon-optimized R338L human FIX cDNA 
as a means to achieve long-term therapeutic levels of human FIX 
in hemophilia B while reducing the risk of adverse effects associ-
ated with integrating vectors.
In earlier publications,21,22 we demonstrated that combining 
the aforementioned modifications in a single human FIX cDNA 
synergistically enhanced the total human FIX activity per vec-
tor genome in vitro by more than 50-fold. However, we reasoned 
that the efficacy and safety of using a highly active human FIX 
cDNA should be evaluated in a long-term in vivo study. A recent 
study demonstrated the ability of IDLV carrying codon-optimized 
R338L human FIX to achieve canine FIX activity of up to 45% of 
normal level in hemophilia B mice,32 but the ability of IDLVs car-
rying human FIX to support a long-term cure for hemophilia B 
mice—without inducing cellular or humoral immune response—
and their long-term biodistribution and number of illegitimately 
integrated vector genomes per host genome have not been docu-
mented. In this study, we demonstrate for the first time the abil-
ity of IDLVs carrying the codon-optimized R338L human FIX 
to achieve a long-term (1-year) cure of hemophilia B in a mouse 
model. Levels of IDLV-delivered human FIX antigen and activity 
were dose dependent. Furthermore, survival of the IDLV-treated 
mice after a challenging tail-clipping assay provided the strongest 
attestation to the therapeutic potential of the IDLV system.
Although the C57BL/6 hemophilia B mice used in this study 
were devoid of all murine FIX coding sequences, long-term expres-
sion of human FIX following IDLV and ICLV administration was 
not associated with either an increase in liver enzymes or with the 
development of inhibitory antibodies to human FIX. These findings 
are in line with an earlier report demonstrating long-term hepatic 
expression of firefly luciferase following gene delivery by IDLV 
and ICLV.6 The lack of immune response to transgene-expressing 
hepatocytes and to circulating human FIX can be attributed in part 
to liver-mediated immune tolerance.33 Of note, in contrast with 
earlier studies,18,25,26 we report that long-term expression of human 
FIX did not require the incorporation of mir142 complemen-
tary sequences as a means to avoid human FIX-directed immune 
response by reducing its expression in hematopoietic cells.
Although novel polypurine tract-deleted vectors, generat-
ing primarily one-long terminal repeat circles, exhibited signifi-
cantly lower levels of illegitimate IDLV integration,28 the ability 
to quantitatively characterize the level of illegitimate integration 
of IDLVs in vivo is required to accurately evaluate their biosafety 
value. In this article, we describe the development of the S1/
B1-qPCR methodology (Supplementary Figure S2). Tervo et al. 
described the two-round, nested B1-qPCR methodology earlier 
as a means to evaluate HIV-1 integration in mouse cell lines in 
vitro.29 However, this study demonstrated significant background 
readouts, which were attributed to linear amplification of HIV-1 
sequences independent of viral integration (Supplementary 
Figure S3). This phenomenon significantly reduces the sensitivity 
of the B1-qPCR system and renders it unsuitable for quantifying 
low levels of IDLV integration in vivo. Thus, to accurately evalu-
ate IDLV integration in mouse liver, three modifications were 
incorporated into the conventional B1-qPCR methodology.29 (i) 
To minimize the synthesis of single-stranded DNA templates, 
the viral anchor primer was directed to sequences upstream to 
the viral polypurine tract (rather than to sequences in the viral 
long terminal repeats; Supplementary Figure S2). (ii) To further 
reduce the levels of single-stranded DNAs, amplification products 
of the first round of PCR were subjected to S1-nuclease degra-
dation before the second nested-PCR round (Supplementary 
Figure S4). (iii) Earlier studies34,35 demonstrated tissue-specific 
patterns of HIV-1 vector integration. Because our studies focused 
on hepatic human FIX delivery, we sought to characterize the rate 
of illegitimate IDLV integration relative to the levels of ICLV inte-
gration in mouse liver. Therefore, the standard curve used in this 
study was based on liver genomic DNA of an ICLV-treated mouse.
The novel S1/B1-qPCR assay, for the first time, allowed accu-
rate detection of low levels of integration and thus facilitated the 
comparative evaluation of the IDLV and ICLV levels of integra-
tion, genotoxicity, and biosafety in vivo. Premised on the S1/
B1-qPCR methodology, we calculated the vector TGI as the over-
all increase in human FIX percentage activity per integrated vec-
tor genome in vivo. The aforementioned results indicate that the 
TGI of IDLVs was nearly 12-fold higher than the calculated index 
obtained for their integrated counterparts. Incorporating the 
highly efficacious humanized R338L into the IDLVs provides the 
ability to cure hemophilia B with reduced vector load. This con-
stitutes a major leap forward in vector biosafety and opens a new 
avenue in the gene therapy of hemophilia B using IDLVs, in addi-
tion to other viral and nonviral-based vectors including adeno-
associated virus-based vectors and naked DNA, respectively.36
Overall, in this study, we demonstrated for the first time that 
IDLVs carrying the codon-optimized R338L human FIX variant 
supported a long-term (1-year) complete cure of hemophilia B in 
a mouse model of FIX deficiency. IDLV-treated hemophilic mice 
survived a challenging tail-clipping assay and did not develop a 
detectable immune response to either vector-delivered human FIX 
or vector-transduced cells. In addition, we report the development 
of a novel S1 nuclease-based B1-qPCR methodology to quantify 
low levels of vector integration in vivo for evaluating the biosafety 
of IDLV gene delivery. The findings of this study indicate that the 
IDLV is a safe and efficacious gene delivery system suitable for gene 
replacement applications in nonterminal genetic diseases.
MAterIAls And Methods
Lentiviral vector constructs. A series of human FIX cDNA fragments, 
including WT cDNA (pTK1201), codon-optimized cDNA (pTK1206), three 
R338 mutants (R338A, pTK912; R338Q, pTK1414; and R338L, pTK1367), 
and each 338-residue mutant on the background of codon-optimized 
human FIX cDNA (codon-optimized R338A, pTK1207; codon-optimized 
R338Q, pTK1336; and codon-optimized R338L, pTK1335), were cloned 
into the Hpa I site of a lentiviral vector (pTK642). All the above human FIX 
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constructs were expressed under the control of the cytomegalovirus pro-
moter and contained an internal ribosome entry site conjugated with the 
green fluorescent protein reporter gene and the blasticidin resistance gene. 
The codon-optimized R338L human FIX cDNA (pTK1340) used in in vivo 
studies was cloned under a liver-specific human α1-antitrypsin promoter.
Lentiviral particle production, concentration, and titration.  All vector-
derived lentiviral particles were produced in 293T cells using three-plas-
mid transient transfection, as previously described.37 Lentiviral vectors 
harboring human FIX cDNA used in the in vitro studies were packaged 
with integrase-competent packaging vector (NRF).37 Codon-optimized 
R338L human FIX (pTK1340) lentiviral vectors used in in vivo studies 
were packaged by either NRF or integrase-defective packaging vector 
(pTK939), which expresses D64E-mutant integrase. Vector titer was deter-
mined by measuring the p24 capsid concentration using enzyme-linked 
immunosorbent assay, as previously described.17 All viral vector prepara-
tions were confirmed for the absence of replication-competent retrovirus, 
as previously documented.38
Generation of HepG2 cell lines stably expressing WT and modified 
human FIX cDNAs. HepG2 cells were transduced with lentiviral vectors 
harboring relevant human FIX constructs at equivalent amounts of p24gag. 
Blasticidin-resistant cells were selected and their VCNs were determined 
using a multiplex qPCR.
Determination of protein concentration and clotting activity of human 
FIX secreted from HepG2 cells.  To compare the yield and clotting func-
tion of human FIX proteins generated from each HepG2 cell line, cells were 
plated at 0.5 × 106 cells per well on a six-well plate for 24 h. Subsequently, 
the culture medium was replaced with fresh medium containing vitamin K 
(Hospira, Lake Forest, IL). After an additional 24-h incubation, the medium 
containing human FIX clotting proteins was collected and analyzed for pro-
tein concentration and clotting activity using enzyme-linked immunosor-
bent assay and activated partial thromboplastin time, respectively.
Determination of human FIX protein concentration and coagulation 
activity.  Human FIX protein concentration was measured using a sand-
wich enzyme-linked immunosorbent assay, modified based on the original 
method described previously.39 Materials and procedures are detailed in 
the Supplementary Materials and Methods. Clotting activity was mea-
sured by activated partial thromboplastin time as previously described,40 
with a minor change in the standard curve, which was generated by per-
forming clotting assay on serial dilutions of a plasma-derived, highly puri-
fied human FIX protein (CSL Behring, King of Prussia, PA).
Animal studies. All procedures involving animal study were performed in 
accordance with the Guide for the Care and Use of Laboratory Animals; the 
in vivo study protocol was approved by the University of North Carolina 
Institutional Animal Care and Usage Committee. The FIX-deficient mouse 
model (murine FIX-knockout C57BL/6 strain) used in this study was 
described previously.41
In vivo coagulation assay. At 20 weeks postviral treatment, mice injected 
with total doses of either 200 or 250 µg p24gag IDLVs were subjected to 
a tail-clipping assay performed under anesthesia, following the proce-
dure described previously.42 Blood was collected into citrated tubes over a 
15-min period. Following tail clipping, mice were monitored hourly for 8 
hours to observe recurrent bleeding; mice experiencing recurrent bleeding 
episodes >8 hours after the tail-clipping procedure required euthanasia.
Evaluation of viral vector toxicity and human FIX-directed inhibitory 
antibodies. As a test of liver function, mouse plasma samples were col-
lected weekly during the first 5 weeks postviral injection and submitted 
to the Animal Clinical Chemistry and Gene Expression Laboratories for 
alanine aminotransferase analysis using an automatic chemical analyzer 
(Johnson & Johnson’s VT350, New Brunswick, NJ). To detect human FIX 
inhibitory antibodies, a modified Bethesda assay was performed according 
to the protocol previously described.42
Preparation of mouse tissue DNA for quantification of VCN. At 1 year 
postviral administration, mouse tissues, including liver, brain, heart, 
lung, spleen, kidney, and bone marrow, were harvested. Genomic DNAs 
were isolated from tissues using a Blood & Tissue DNeasy kit (Qiagen, 
Valencia, CA), according to the manufacturer’s instructions; RNAs were 
removed using RNase A (Fermentas, Pittsburgh, PA). All samples were 
treated with DpnI (New England Biolabs, Ipswich, MA). Total VCN and 
integrated vector genomes were quantified using multiplex qPCR and S1/
B1-qPCR, respectively.
Multiplex qPCR. Multiplex qPCR is a probe-based PCR optimized in this 
study for use in quantification of HIV-1 VCNs. Amplifications of both vec-
tor and reference gene are carried out simultaneously in a single PCR reac-
tion using two different readout probes. The multiplex qPCR approach is 
uniquely designed to quantify vector genomes in both human and mouse 
systems (using an identical set of primers/probe for vector amplification, and 
a relevant reference gene; β-glucuronidase for humans and glyceraldehyde-
3-phophate dehydrogenase for mouse). Materials and procedures used in the 
multiplex qPCR are detailed in the Supplementary Materials and Methods.
S1/B1-qPCR. The novel S1/B1-qPCR was optimized based on the conven-
tional B1-qPCR29 to enable accurate quantification of integrated vector 
genomes in sample DNAs containing episomal viral vector genomes. The 
protocol, including sequences of primers and probes, is provided in the 
Supplementary Materials and Methods.
Integration site analysis. The pattern of vector integration mediated by 
ICLVs and IDLVs was assessed at 1 year postviral treatment. DNA samples 
extracted from liver tissues of hemophilia B mice, injected with either 
IDLV or ICLV at 65 µg p24gag (n = 3 per group), were mapped to identify 
vector ISs using non-restrictive LAM-PCR and LAM-PCR, followed by 
454 pyrosequencing, as previously described.30,31
suPPleMentArY MAterIAl
Figure S1. Hematoxylin/eosin staining of tumor-containing liver and 
spleen tissues.
Figure S2. Optimization of the S1/B1 qPCR methodology.
Figure S3. Significant background amplification of nonintegrating 
vector genomes by conventional nested B1-qPCR in the absence of 
the B1-directed primers.
Figure S4. S1-nuclease treatment reduces background B1-qPCR am-
plification of nonintegrating HIV-1 vectors.
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